Trial Profile
Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Guadecitabine (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 18 Feb 2023 Status changed from active, no longer recruiting to completed according to results presented at the 2023 Genitourinary Cancers Symposium
- 18 Feb 2023 Final results presented at the 2023 Genitourinary Cancers Symposium
- 16 Feb 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.